Secondary Logo

Journal Logo

Original Article

Video-assisted thoracoscopic surgical decortication in the elderly with thoracic empyema: Five years’ experience

Tsai, Chien-Hoa,b; Lai, Yi-Chunb,c; Chang, Shih-Chiehb,c; Chang, Cheng-Yue; Wang, Wei-Shub,c; Yuan, Mei-Kangb,d,*

Author Information
Journal of the Chinese Medical Association: January 2016 - Volume 79 - Issue 1 - p 25-28
doi: 10.1016/j.jcma.2015.06.013

    Abstract

    1. Introduction

    Pleural effusion develops in 40% of pneumonia patients, but only 15% of patients develop thoracic empyema after antibiotic treatment.1 Many studies have revealed increasing case numbers of empyema in elderly patients.2,3 There are three stages of empyema, exudative (Stage I), fibropurulent (Stage II), and organizational (Stage III), which present a continuous course of inflammatory process and should be managed by different medical interventions.4 The exudative stage can usually be handled with tube drainage and appropriate antibiotic treatment, and seldom needed surgical intervention.5 The second fibropurulent or third organizational stage often needed tube thoracotomy or surgical decortication because of fibrin depositions with pleural peels.5 The mortality of thoracic empyema was 10–20%.6–8 The treatment of empyema needs adequate antibiotic use and drainage by tube thoracotomy or surgical intervention according to the particular empyema stage and the patient's condition.6–8 Recently, an increasing number of studies have favored the approach of video-assisted thoracoscopic (VATS) decortication in thoracic empyema treatment.9–12 One study displayed VATS decortication with a higher successful treatment rate (91% vs. 44%) and shorter hospital stay (8.7 days vs. 12.8 days) compared with the group with tube thoracotomy alone.13 A meta-analysis,14 which reviewed 14 large studies, showed VATS decortication had shorter total hospital stay (15 days vs. 21 days, p = 0.03) and fewer postoperation complications, such as atelectasis (p = 0.006) and mortality (p = 0.02), when compared with open decortication. However, the role of VATS decortication in the older population had been rarely reported. Considering the worldwide trend of aging population society in the near future, the best strategy to treat aging and fragile patients with thoracic empyema should be further investigated. Therefore, this study analyzed the outcome and complications of thoracic empyema in older patients treated by VATS decortication in our hospital.

    2. Methods

    2.1. Study population

    This was a retrospective study in National Yang-Ming University Hospital, Yilan City, Taiwan, a 400-bed regional teaching hospital that offers clinical services. From January 2006 to August 2011, we collected those patients with thoracic empyema and treated with VATS decortication. The patient inclusion criteria were (1) older than 65 years; (2) a patient of thoracic empyema; and (3) accepted VATS decortication. Exclusion criteria included patients under long-term ventilator support and patients with septic shock and cardiopulmonary distress. Pleural fluid was obtained by tube thoracotomy or thoracentesis. The definition of empyema was satisfying at least one of the following criteria: (1) pus-like material in the pleural cavity; (2) a positive report of Gram stain or pleural effusion culture for the microorganisms; and (3) pleural effusion analysis with pH ≤ 7.2, glucose level ≤ 40 mg/dL, and lactic dehydrogenase (LDH) level ≥ 1000 U/L.15 We reviewed the demographic data, comorbidities, clinical symptoms, images, and laboratory data, including pleural fluid and culture report, for evaluation of the morbidity and mortality. The study was approved by the authors’ institutional review board (IRB No. 2010A015).

    2.2. Surgical technique

    We performed VATS decortication with general anesthesia using double-lumen endotracheal tube insertion. After skin preparation and sterilization, two incisions over the lesion site with a 1-cm-length wound in the crossing of the eighth intercostal space and the midaxillary line for camera, and another 3-cm-length wound in the anteriorly fifth intercostal space for access. Also, the two incision wounds allowed surgical instruments to deal with the empyema.14,16 The decortication was performed using forceps and scissors by a well-experienced chest surgeon.14

    2.3. Statistical analysis

    Statistical analyses were performed using SPSS software version 15.0 (SPSS, Inc., Chicago, IL, USA). The patient data were described by frequency for categorical variables, and by mean ± standard deviation for numeric variables.

    3. Results

    3.1. Patient characteristics

    In total, 33 patients older than 65 years accepted VATS decortications for thoracic empyema. The characteristics of the 33 patients are listed in Table 1. The mean age was 73.6 ± 7.1 years. Twenty-one (63.6%) patients were male. The preoperative comorbidities of the 33 patients were presented with the Charlson comorbidity index. Twenty-four (72.7%) of the empyema patients were categorized as being in the fibropurulent stage, five (15.2%) were in the exudative stage, and four (12.1%) were in the organizational stage.4 The laboratory data showed a mean white blood cell count of 16.1 ± 8.9 × 109/L, and mean C reactive protein of 21.5 ± 11.1 mg/dL. The most common symptoms were cough (78.8%), followed by fever (72.67%; Table 2). The major etiology of thoracic empyema was pneumonia (87.9%; Table 2).

    Table 1
    Table 1:
    Demographic data of patients.
    Table 2
    Table 2:
    Clinical presentation and etiology of thoracic empyema.

    3.2. Pleural effusion analysis

    In thoracic empyema, we found 14/31 (45.2%) patients with positive Gram stain or culture of pleural effusion (Table 3). All enrolled patients received antibiotic treatment before VATS because of the clinical presentation of fever, cough, and lung opacities by chest images during the initial hospitalization. The most common pathogens were Klebsiella pneumonia (3 patients), Streptococcus spp. (3 patients), and Acinetobacter baumannii (3 patients).

    Table 3
    Table 3:
    Microbiological data of thoracic empyema.

    In pleural effusion laboratory analysis (Table 4), the mean white blood cell count was 13.5 ± 19.7 × 109/L, mean LDH of 2951 ± 4380 U/L, and mean glucose level of 51.2 ± 53.6 mg/dL.

    Table 4
    Table 4:
    Pleural fluid laboratory analysis.

    3.3. Radiologic analysis

    The postoperative chest plain radiographs and computed tomography images were reviewed by radiologists and pulmonologists in comparison with the preoperative images. The final decisions on staging of empyema before surgery, disease improvement or progression on discharge, and partial or good expansion of the affected lung 90 days after discharge were determined by consensus.17

    3.4. Postoperative morbidity and mortality

    The mean hospital stay was 27.5 ± 14.5 days. Only one patient died of progressive sepsis, due to pulmonary infection 9 days after VATS decortication. The 30-day mortality was 3% after the surgery. Two patients (6.2%) had recurrent or persistent empyema, and we performed mini-thoracotomy on them 3 months later. The main postoperative morbidities included respiratory failure requiring mechanical ventilation for >7 days (15.2%) and septic shock (15.2%), followed by persistent air leakage for >7 days (9.1%; Table 5). Twenty-seven (84.4%) of 32 patients were stable on discharge, and 24 (75%) of these patients had good expansion of the affected lung 3 months after VATS decortication.

    Table 5
    Table 5:
    Postoperative complications and recovery evaluation.

    4. Discussion

    In our study, we found that in aged patients (older than 65 years) with thoracic empyema, VATS decortication is an effective treatment. The most common complications after VATS decortication were respiratory failure and sepsis.

    Older people usually have atypical presentation of thoracic empyema, with less chest pain and fever but more dyspnea than younger patients, which makes empyema early diagnosis difficult.18 Due to age-related physiologic function decline and comorbidities, older patients often have higher mortality rate with thoracic empyema.2 Mandal et al19 reported that the mortality rate is 50% in patients older than 65 years, compared with patients younger than 65 years (only 3.6% mortality). The older patients in the current study were classified as moderate (Category 3) or high (Category 4) risk for a poor outcome according to American College of Chest Physicians (ACCP) guideline,20 but we had a lower post-VATS mortality rate and acceptable morbidities. A study in Taiwan in 2005 revealed that the overall 100-day-in-hospital mortality for thoracic empyema in older patients (>65 years) was 13% and only 8% in younger patients.17 The empyema mortality of older patients seems to have improved in recent decades, which may be related to diagnostic tools, surgical techniques, and health care improvements.18,21

    VATS decortication uses less operation time and fewer hospital days compared with open decortication.5,12 One large series of thoracic decortications comparing VATS and open procedures for 420 patients revealed the operation time in VATS decortication was 97 minutes, while in open decortication it was 155 minutes (p < 0.001).5 The median postoperative stay was shorter for VATS decortication patients compared with open decortication patients (7 days vs. 10 days, p < 0.001). In addition, there were fewer postoperative complications, such as atelectasis and reintubation in the VATS decortication group.5,14 In our study, the mean hospital stay was longer (27.5 days) than previous reports,5,12 as the patients were older in our study (73.6 years vs. 55 years). However, the 30-day mortality was only 3% in our study, which was similar with previous studies.19 Eleven cases (33%) were diagnosed with coexisting lung abscess in our study. Under the minimally invasive principle, we did not perform unroofing or pulmonary resection. We used adequate chest tube position in addition to the self-ruptured abscess opening in the pleural cavity instead of extensive eradication of the abscess.

    There were some limitations to the current study. This was a retrospective study with a relatively small sample size. However, we focused on the elderly group receiving VATS decortication, which has been less discussed previously. We still require a larger case number of older patients receiving VATS decortication to establish a guideline for thoracic empyema treatment in the future.

    In conclusion, we think that VATS decortication in the treatment of thoracic empyema is effective in elderly patients.

    References

    1. Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc. 2006;3:75-80.
    2. Smith JA, Mullerworth MH, Westlake GW, Tatoulis J. Empyema thoracis: 14-year experience in a teaching center. Ann Thorac Surg. 1991;51:39-42.
    3. Alfageme I, Muñoz F, Peña N, Umbria S. Empyema of the thorax in adults. Etiology, microbiologic findings, and management. Chest. 1993;103:839-843.
    4. Hamm H, Light R. Parapneumonic effusion and empyema. Eur Respir J. 1997;10:1150-1156.
    5. Tong BC, Hanna J, Toloza EM, Onaitis MW, D’Amico TA, Harpole DH, et al. Outcomes of video-assisted thoracoscopic decortication. Ann Thorac Surg. 2010;89:220-225.
    6. Ferguson AD, Prescott RJ, Selkon JB, Watson D, Swinburn CR. The clinical course and management of thoracic empyema. QJM. 1996;89:285-289.
    7. Farjah F, Symons RG, Krishnadasan B, Wood DE, Flum DR. Management of pleural space infections: a population-based analysis. J Thorac Cardiovasc Surg. 2007;133:346-351.
    8. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005;352:865-874.
    9. Waller DA, Rengarajan A. Thoracoscopic decortication: a role for video-assisted surgery in chronic postpneumonic pleural empyema. Ann Thorac Surg. 2001;71:1813-1816.
    10. Rzyman W, Skokowski J, Romanowicz G, Lass P, Dziadziuszko R. Decortication in chronic pleural empyema—effect on lung function. Eur J Cardiothorac Surg. 2002;21:502-507.
    11. Luh SP, Chou MC, Wang LS, Chen JY, Tsai TP. Video-assisted thoracoscopic surgery in the treatment of complicated parapneumonic effusions or empyemas: outcome of 234 patients. Chest. 2005;127:1427-1432.
    12. Cardillo G, Carleo F, Carbone L, Di Martino M, Salvadori L, Petrella L, et al. Chronic postpneumonic pleural empyema: comparative merits of thoracoscopic versus open decortication. Eur J Cardiothorac Surg. 2009;36:914-918.
    13. Wait MA, Sharma S, Hohn J, Dal Nogare A. A randomized trial of empyema therapy. Chest. 1997;111:1548-1551.
    14. Shahin Y, Duffy J, Beggs D, Black E, Majewski A. Surgical management of primary empyema of the pleural cavity: outcome of 81 patients. Interact Cardiovasc Thorac Surg. 2010;10:565-567.
    15. Heffner JE, Brown LK, Barbieri C, DeLeo JM. Pleural fluid chemical analysis in parapneumonic effusions: a meta-analysis. Am J Respir Crit Care Med. 1995;151:1700-1708.
    16. Burfeind WR DAT. Thoracoscopic lobectomy. Oper Tech Thorac Cardiovasc Surg. 2004;9:98-114.
    17. Casali C, Storelli ES, Di Prima E, Morandi U. Long-term functional results after surgical treatment of parapneumonic thoracic empyema. Interact Cardiovasc Thorac Surg. 2009;9:74-78.
    18. Tsai TH, Jerng JS, Chen KY, Yu CJ, Yang PC. Community-acquired thoracic empyema in older people. J Am Geriatr Soc. 2005;53:1203-1209.
    19. Mandal AK, Thadepalli H, Mandal AK, Chettipally U. Outcome of primary empyema thoracis: therapeutic and microbiologic aspects. Ann Thorac Surg. 1998;66:1782-1786.
    20. Colice GL, Curtis A, Deslauriers J, Heffner J, Light R, Littenberg B, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest. 2000;118:1158-1171.
    21. Singer BH, Manton KG. The effects of health changes on projections of health service needs for the elderly population of the United States. Proc Natl Acad Sci U S A. 1998;95:15618-15622.
    Keywords:

    elderly; thoracic empyema; video-assisted thoracoscopic decortication

    © 2016 by Lippincott Williams & Wilkins, Inc.